Indirubin is definitely an active component of a classic Chinese prescription, Dang Gui Hui Wan utilized in treating chronic myelogenous leukemia. Numerous studies have shown that indirubin inhibits cyclin dependent kinases in tumor cells, and therefore inhibits cell Cabozantinib structure proliferation in the late G1 and G2/M cycle through the relationship using the kinases ATP binding site. Previous study reported the novel indirubin derivative, 5 nitro indirubinoxime has livlier anti-tumor activity in vitro and in vivo than any other reported indirubin types. 5 NIO can also supposedly inhibits TNF ainduced monocyte chemoattractant protein 1 and interleukin 8 expression at the protein and RNA levels in HUVECs, suggesting that5 NIO gets the possibility of use being an agent. Although many studies on the scientific activities have been performed, with specific focus on its anti tumorigenic activity, it’s unclear whether 5 NIO inhibits the neoplastic transformation and AP 1 transactivation activity induced messenger RNA (mRNA) by tumor promoter, including epidermal growth factor and 12 E tetradecanoylphorbol 13 acetate. Activator protein acts as pivotal transcription issue concerning neoplastic transformation and development of cancer, and is regulated by upstream kinases, including mitogen-activated protein kinases. The RAS MAPK signaling pathway is usually upregulated in various cancer cell types, and this pathway can be considered a beautiful pathway for anticancer therapies, depending on its key role in controlling the development and survival of cells from the broad-spectrum of human tumours. Among the aspects of the MAPK pathways, the MAPK kinase kinase /MAPK kinase /extracellular signal-regulated kinase cascade is the target of cancer chemotherapy due to its relevance in carcinogenesis. A number of tumor promoters including TPA and EGF are known to induce neoplastic transformation through activation of Raf/MEK/ERK pathway in several Apremilast cell lines. The JB6 Cl41 mouse epidermal cell process is regarded as a proper model for learning cyst promoter induced carcinogenic processes at the molecular level. Today’s research aimed to elucidate the molecular mechanism of the effects of indirubin by-product, 5 NIO, on EGF or TPA induced neoplastic transformation of JB6 Cl41 cells, respectively. Here, we report that 5 NIO is a potent inhibitor of Pin1 phosphorylation at serine 16. The inhibition of Pin1 phosphorylation at serine 16 suppressed its connection with Raf 1 and Raf 1/MEK/ERK signaling pathway, which consequently inhibited neoplastic transformation and AP 1. 5 NIO also inhibited JNK/c Jun signaling pathway, triggered inhibition of c jun promoter activity. As the prolyl isomerase Pin1 comes with an important role in tumorigenesis, the with this investigation may provide new insights in the mechanism of 5 NIO in anticarcinogenesis and the possibility for its application in tumor prevention and treatment.